Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

poster presentations, Poniard will host an investor event on Sunday, June 1, at 6:30 p.m. in Chicago. The event will feature presentations and discussion with expert oncologists, including lung cancer expert Chandra Belani, M.D., of the University of Pittsburgh Medical Center; prostate cancer expert E. David Crawford, M.D., of the University of Colorado Health Sciences Center in Denver; and platinum therapy developer, Lloyd Kelland, Ph.D., of Cancer Research Technology and University College London, in addition to members of Poniard's senior management. For more information or to rsvp to the event, please email rsvp@poniard.com.

About Picoplatin

Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company is also evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of HRPC, and an ongoing Phase 2 clinical trial in patients with patients with metastatic CRC. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The oral formulation of picoplatin has the same active pharmaceutical ingredient as the intravenous formulation. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biop
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... -- Eight finalists, all representing outstanding innovation in pediatric ... for a chance to compete for one of two ... Second Annual Pediatric Surgical Innovation Symposium hosted by ... 24, 2014. Selected from a competitive field ... internationally, the finalists are: , Creative ...
(Date:10/16/2014)... , Oct. 16, 2014   NuVascular ... process to create new medical devices that help ... Inc., the company uses cutting-edge nanotechnology that would ... kidney diseases.  The platform technology ... result of $6.6 million in funding obtained from ...
(Date:10/16/2014)... 2014 Ninety percent of children and adults ... times or failed to respond to standard therapies went ... CTL019, developed at the Perelman School of Medicine at ... The New England Journal of Medicine ... preliminary findings presented at the American Society of Hematology,s ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... Inc. (Nasdaq: BNVI ), a pharmaceutical company focused ... for women,s health and cancer, today announced the pricing of ... 30,031,200 units at a price per unit of $1.00 for ... of one share of common stock and a warrant to ...
... Information Systems ("SIS"), a leader in perioperative ... successfully completed the healthcare industry,s week-long interoperability ... Connectathon. (Logo: http://photos.prnewswire.com/prnh/20080722/SISLOGO) ... industry,s largest interoperability testing event designed to ...
Cached Medicine Technology:Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants 2Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants 3Surgical Information Systems Completes IHE North American Connectathon 2
(Date:10/19/2014)... NY (PRWEB) October 19, 2014 Nearly ... Bard Inc. and Johnson & Johnson’s Ethicon unit have ... Court, where two state proceedings are continuing to move ... 7,201 lawsuits have been filed over products part of ... Case List updated on October 11th, 2014, which showed ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 According to ... (NINDS) the vast majority of adults (up to ... point in their lives, spending at least $50 billion ... pain includes; spinal instability, stenosis, spondylolisthesis, and symptomatic degenerative ... by wear and tear associated with the aging process, ...
(Date:10/18/2014)... New Providence, NJ (PRWEB) October 19, 2014 ... service consulting company, took part in the breast cancer ... Pink is a national movement of pink pajama parties ... breast cancer survivors. , In support of the ... a group photo to the Estroven Facebook Page. In ...
(Date:10/18/2014)... natural opioid system in the brain. Now new research, ... that the opioid system of pathological gamblers responds differently ... carried out by a group of UK researchers from ... Research Council. This work is being presented at the ... a widespread behaviour with about 70% of the British ...
(Date:10/18/2014)... October 18, 2014 Mirena lawsuits ( ... to sustain serious injuries when it spontaneously migrated from ... in U.S. courts, Bernstein Liebhard LLP reports. According to ... Panel on Multidistrict Litigation (JPML) on October 15th, at ... multidistrict litigation underway in the U.S. District Court, Southern ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 2Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 4Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 5Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 2Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 3Health News:Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4
... fibrosis kills 40,000 Americans each year , , FRIDAY, May ... of the lungs that,s fatal within a few years ... , Japanese researchers say daily use of the drug ... of patients with the illness, called idiopathic pulmonary fibrosis ...
... When Jon Ziefert and Steve Smith were,recovering from ... food gift baskets. "Some were healthy but most ... ... was highly,perishable. So they had to give most of ... and other high-sugar, high-fat foods simply had no,place in ...
... 32, was indicted by a grand jury in ... the operation of an,illegal Internet pharmacy, Assistant Attorney ... U.S. Attorney Patrick L. Meehan for the,Eastern District ... charged with four counts of distribution of controlled,substances ...
... Thousands of Schoolchildren Get Active To Follow Along Online, ... top a successful,expedition to the top of the world ... of schoolchildren on the Web? Climb another,mountain? How about ... 50 states --,and do it in 50 days or ...
... the Texas Annual,Conference of the United Methodist Church will ... success of the Nothing But Nets,campaign and the groundbreaking ... The Woodlands UMC will host the event, Sunday,through Wednesday, ... May 28 at 10:45 a.m., will affirm,the covenant relationship ...
... New data, generated by Shahin Rafii and colleagues, at Weill ... human colon cancer cells and mice, have shed doubt on ... marker of colon cancer stem cells a term given ... that are thought to be able to give rise to ...
Cached Medicine News:Health News:Drug for Deadly Lung Disease Shows Promise 2Health News:Drug for Deadly Lung Disease Shows Promise 3Health News:Cancer Survivors Develop Healthy Food Gift Business 2Health News:California Man Indicted For Conspiracy In Operating Internet Pharmacy 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 3Health News:Local Methodists Host West African Choir, South African Leader at Historic Conference 2
... color touch screen shows you the ... cassette it is ready-to-go in any ... assures accurate calibration prior to each ... with a removable, rechargeable battery, which ...
... The ABL800 FLEX is a ... Radiometers most advanced blood gas analyzer ... that gives you the freedom to ... ABL800 FLEX provides features that are ...
Flatbed Agitator....
Flatbed Agitator....
Medicine Products: